Sacral Neuromodulation for the Treatment of Chronic Pelvic Pain

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Sacral neuromodulation (SNM) is a safe, effective, and minimally invasive FDA approved treatment for urinary and fecal incontinence, urinary frequency, urgency, and urinary retention. In this study we are assessing the effectiveness of sacral neuromodulation in women with suffering from chronic pelvic pain (CPP), through a single device implant procedure.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 22
Maximum Age: 70
Healthy Volunteers: f
View:

• Provision of signed and dated informed consent form

• Stated willingness to comply with all study procedures and availability for the duration of the study

• Female, aged 22-70

• Chronic pelvic pain (= pain below umbilicus) score of 4 or greater on 10-point VAS, present for 6 months or greater (screening patient)

• Failed at least 1 or more conservative treatments (e.g. pelvic floor physical therapy, biofeedback, behavioral modification, oral pharmacotherapy, bladder instillations)

• No changes to current regimen of medications for their pelvic pain for \> 4 weeks prior to screening

• For females of reproductive potential: use of highly effective contraception (e.g. licensed hormonal or barrier methods), for at least 1 month prior to screening and agreement to use such a method during study participation

• Participant agrees not to start any new treatment interventions for CPP prior to Visit 4 (Primary Endpoint)

Locations
United States
Michigan
Corewell Health William Beaumont University Hospital
RECRUITING
Royal Oak
Contact Information
Primary
Angela Waldvogel, BSN
Angela.Waldvogel@corewellhealth.org
248-551-2572
Backup
Jennifer Giordano, BSN
jennifer.giordano@corewellhealth.org
248-551-3517
Time Frame
Start Date: 2025-06-30
Estimated Completion Date: 2028-12-01
Participants
Target number of participants: 25
Treatments
Experimental: SNM for the treatment of CPP
Patients will be enrolled based on study eligibility criteria. Eligible patients will be scheduled for a Interstim X implant in the operating room. The procedure is completed under anesthesia, either conscious sedation with intubation or breathing assistance. Under fluoroscopic guidance a standard lead will be introduced. Each electrode on the lead will be tested by confirming motor response on at least 3 of 4 leads. Next the implantable pulse generator will be placed in a subcutaneous pocket and secured. Impedance will be tested, 4 standard programs will be set, and then the device will be shut off. The device settings will be adjusted per protocol and the device will be turned on and off during visits 2-7.
Sponsors
Leads: William Beaumont Hospitals

This content was sourced from clinicaltrials.gov